Filing Date |
T Date |
Ticker |
Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
3/12/19 16:38 | 3/6/19 | NTLA | Health | Diagn | In Vitro & In Vivo Diagnostic | Schiermeier Andrew | MA | O | EVP,Dev, | P | 118 | 15.72 | 0 | 8 | 87 | 16 | D | ||||||||||||||
5/13/16 16:58 | 5/11/16 | NTLA | Health | Diagn | In Vitro & In Vivo Diagnostic | Orbimed Advisors LLC | NY | D | P.d | 4,500 | 18.00 | 33 | 250 | 10 | 2,662 | I | -2 | 7 | 13 | 14 | -23 | -38 | |||||||||
5/13/16 06:15 | 5/11/16 | NTLA | Health | Diagn | In Vitro & In Vivo Diagnostic | Temasek Holdings (Private) Ltd | U0 | T | P.d | 5,400 | 18.00 | 33 | 300 | 31 | 1,281 | I | -2 | -1 | 13 | 13 | -24 | -39 | |||||||||
5/11/16 18:57 | 5/11/16 | NTLA | Health | Diagn | In Vitro & In Vivo Diagnostic | Novartis Institutes For Biomedical Research, Inc. | MA | T | P.d | 5,000 | 18.00 | 33 | 278 | 5 | 5,574 | D | -7 | 4 | 7 | -25 | -41 | ||||||||||
5/11/16 18:36 | 5/11/16 | NTLA | Health | Diagn | In Vitro & In Vivo Diagnostic | Gordon Carl L | MA | D | P.d | 4,500 | 18.00 | 33 | 250 | 10 | 2,662 | I | -7 | 4 | 7 | -25 | -41 | ||||||||||
5/11/16 16:25 | 5/11/16 | NTLA | Health | Diagn | In Vitro & In Vivo Diagnostic | Baker Bros. Advisors LP | NY | H | Former 1 | P.d | 3,600 | 18.00 | 33 | 200 | 26 | 976 | I | -7 | 4 | 7 | -25 | -41 |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |